Movement Disorders

Neurology News Network. for the week ending April 26, 2025. [WATCH TIME: 3 minutes]

NLX-112 demonstrated safety and potential efficacy in reducing levodopa-induced dyskinesia and improving motor symptoms in Parkinson disease, with additional benefits seen in patients also receiving stable amantadine.

In this segment, Pagan talked about how the field of neurology has changed in the last decade and shared where he sees it moving forward as well.

Roche has updated its phase 2 GENERATION HD2 trial to continue testing only the higher 100 mg dose of tominersen, following interim data favoring its potential clinical benefit in Huntington disease.

Pagan shared insights from InfusON patient interviews on the challenges and benefits of initiating CSAI therapy and discussed how expert roundtable recommendations can guide neurologists in managing skin nodules associated with treatment.

In this phase 2 trial, TTNS using the Geko device was safe and well tolerated but showed no significant benefit over sham in improving urinary symptoms in Parkinson disease.

Pagan discusses the excitement surrounding new therapeutics in neurodegenerative diseases and how advances in protein clearance and inflammation reduction could lead to disease-modifying treatments for conditions like Parkinson disease.

Fernando L. Pagan, MD, discussed how continuous subcutaneous apomorphine infusion impacts long-term motor fluctuations in Parkinson disease, highlighting InfusON extension study findings on uninterrupted "good ON" time and reduced "OFF" periods as evidence of its real-world efficacy.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 18, 2025.

The chief scientific officer of the Parkinson’s Foundation discussed the foundation’s efforts to integrate whole genome sequencing into PD GENEration and expand access across diverse global populations. [WATCH TIME: 4 minutes]

Philip Kremer, MD, Research Director Neurology, Center for Human Drug Research, provided clinical insights on the early-stage progress of ARV-102, an LRRK2 degrader, in LRRK2-associated diseases.

In late-breaking findings from the TRANQUIL study presented at AAN 2025, the wearable demonstrated significant improvements in tremor reduction and daily functioning over a sham device.

Here's some of what is coming soon to NeurologyLive® this week.

The physician assistant at UCSF Movement Disorder and Neuromodulation Center reflected on the value of AMDAPP in fostering professional connection, education, and patient-centered care among movement disorder APPs. [WATCH TIME: 3 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on essential tremor.

ARV-102 showed dose-dependent LRRK2 degradation and favorable safety in its first-in-human trial, supporting its promise for treating LRRK2-linked neurodegenerative diseases.

Cleveland Clinic’s $1.1 billion Neurological Institute, opening in 2027, will revolutionize neurological care with a state-of-the-art, patient-centered design integrating advanced technology and innovative care solutions.

Findings from a phase 3 study revealed that patients with Parkinson disease switching to IPX203 had greater benefits in good ON time when also taking lower doses of dopamine agonists.

Here's some of what is coming soon to NeurologyLive® this week.

Mark Roskey, PhD, chief scientific officer at Quanterix, provided clinical insight on the function of the company’s Simoa technology and the incorporation of various biomarkers to aid in the diagnosis of Alzheimer disease.

Presented at the 2025 AD/PD Conference, the study incorporates patient engagement in its design and implementation, focusing on optimizing study accessibility, reducing burden, and evaluating glovadalen’s potential as an adjunctive treatment for PD.

A pilot study, presented at the 2025 AD/PD conference, evaluating the CUE1 device suggests it may help improve motor symptoms and reduce fall risk in patients with Parkinson disease.

A recent study reported that silmitasertib, an investigational drug currently in development for cancer, may help reduce motor deficits and neuropathology in a Huntington disease.

Here's some of what is coming soon to NeurologyLive® this week.